ENDAVA (NYSE: DAVA) INVESTOR ALERT: HAGENS BERMAN ENCOURAGES DAVA INVESTORS WITH SUBSTANTIAL LOSSES TO CONTACT FIRM BEFORE NOVEMBER 30 DEADLINE IN SECURITIES CLASS ACTION

Endava ADSs fell more than 24% to $2.11 on Sept. 22, 2026, after the company disclosed an Audit Committee investigation into concerns about customer and supplier agreements, placed its CFO on administrative leave, and delayed its FY2026 annual results. Endava later said certain agreements lacked economic substance and that it would restate quarterly FY2026 financial statements. A securities class action alleges misleading statements about financial condition, internal controls, and revenue recognition; investors seeking lead-plaintiff appointment face a Nov. 30, 2026 deadline.

Analysis

The material risk is not the class-action deadline; it is whether the restatement reveals a durable gap between reported revenue and cash-backed, economically substantive work. If that gap is meaningful, investors may have to reset the revenue base and discount management’s forecasts until audited filings and controls are credible. The secondary effects could include slower client approvals, tougher contract scrutiny, and hiring or delivery disruption—risks that would accrue to Endava specifically, not automatically to the broader IT-services sector. Competitors such as Accenture, Cognizant, Globant and EPAM could benefit at the margin if clients reallocate work, but there is no evidence here of client departures.

The lawsuit notice is largely procedural and should be a weak incremental catalyst versus the accounting investigation. Near term, expect volatility around the delayed filing, investigation findings and auditor conclusions. Over 1–3 months, the key repricing variables are the restatement’s scope, whether prior-period revenue or balance-sheet items change materially, and whether management can provide a reliable filing timetable. Over 6–18 months, control remediation and customer retention determine whether the issue is a temporary reporting shock or a lasting impairment to growth and valuation. Contrarian point: the sharp prior selloff may have absorbed headline litigation risk, but cannot establish that fundamental downside is priced; without verified restated accounts, valuation and recovery cases are not underwritable.

Key Decisions for Investors

• Do not treat the Nov. 30 lead-plaintiff deadline as a standalone short catalyst. The procedural milestone does not resolve the allegations or quantify the accounting impact.
• Keep DAVA on a high-risk watchlist rather than initiate a directional position on this notice alone. Reassess after the restated filings and auditor conclusions; verify the size and nature of adjustments, cash conversion, customer concentration, liquidity and any financing or covenant constraints.
• For existing exposure, size risk to the possibility that restated results materially weaken the earnings base; avoid averaging down before the filing timetable and control remediation are credible. A thesis of stabilization is falsified by further filing delays, broader restatements, auditor qualification or evidence of customer attrition.
• Monitor Accenture, Cognizant, Globant and EPAM for client wins or hiring signals, but do not assume share transfer absent evidence. A relative-value trade is premature until Endava-specific customer losses or competitor gains are observable.